PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis

  • Authors:
    • Luyan Shen
    • Boyang Sun
    • Jiyao Sheng
    • Sihang Yu
    • Yanqing Li
    • Huadan Xu
    • Jing Su
    • Liankun Sun
  • View Affiliations

  • Published online on: May 9, 2018     https://doi.org/10.3892/ijo.2018.4401
  • Pages: 404-416
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The induction of lesions in nuclear and mitochondrial DNA by cisplatin is only a small component of its cytostatic/cytotoxic activity. The signaling pathway network in the nucleus and cytoplasm may contribute to chemotherapeutic resistance. Peroxisome proliferator-activated receptor-coactivator 1α (PGC1α)-mediated mitochondrial biogenesis regulates mitochondrial structural and the functional adaptive response against chemotherapeutic stress, and may be a therapeutic target. However, this regulatory network is complex and depends upon tumor types and environments, which require further investigation. Our previous study found that cisplatin-resistant ovarian epithelial carcinoma was more dependent on mitochondrial aerobic oxidation to support their growth, suggesting the association between mitochondrial function and chemotherapeutic resistance. In the present study, it was demonstrated that the expression of PGC1α and level of mitochondrial biogenesis were higher in cisplatin-resistant SKOV3/DDP cells compared with cisplatin-sensitive SKOV3 cells. Furthermore, SKOV3/DDP cells upregulated the expression of PGC1α and maintained mitochondrial structural and functional integrity through mitochondrial biogenesis under cisplatin stress. Inhibiting the expression of PGC1α using short hairpin RNA led to the downregulation of mitochondrial biogenesis and high levels of apoptosis in the SKOV3/DDP cells, and cisplatin resistance was reversed in the PGC1α-deficient SKOV3/DDP cells. Collectively, the present study provided evidence that cisplatin stimulated the expression of PGC1α and the upregulation of mitochondrial biogenesis through PGC1α, promoting cell viability and inhibiting apoptosis in response to cisplatin treatment, thus triggering cisplatin resistance in ovarian cancer cells.
View Figures
View References

Related Articles

Journal Cover

July 2018
Volume 53 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Shen, L., Sun, B., Sheng, J., Yu, S., Li, Y., Xu, H. ... Sun, L. (2018). PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis. International Journal of Oncology, 53, 404-416. https://doi.org/10.3892/ijo.2018.4401
MLA
Shen, L., Sun, B., Sheng, J., Yu, S., Li, Y., Xu, H., Su, J., Sun, L."PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis". International Journal of Oncology 53.1 (2018): 404-416.
Chicago
Shen, L., Sun, B., Sheng, J., Yu, S., Li, Y., Xu, H., Su, J., Sun, L."PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis". International Journal of Oncology 53, no. 1 (2018): 404-416. https://doi.org/10.3892/ijo.2018.4401